In 2025, expect to see a continued emphasis on minimizing the environmental footprint of congress booths without compromising ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

In her first Ask Alex article of the year, Scientific Director, Dr Alexandra Loveday explores the ways our expert writers ...

In her latest Ask Alex article, Principal Medical Writer, Dr Alexandra Loveday explores modular content and whether it holds ...

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

In its latest update of AXS-05, Axsome reported that the 295-patient phase 3 ACCORD-2 trial met its primary endpoint, with ...

The phase 3 POETYK PsA-1 trial evaluated the drug in patients who were not previously treated with a biologic ...

The Vivactis Group is one of the world’s largest independent healthcare consulting, communications, and marketing networks. Vivactis Global Health draws upon their rich local knowledge to develop ...

Novo Nordisk has announced an investment of 8.5bn Danish kroner, or approximately $1.2bn, to establish a new rare disease production facility in Odense, Denmark. Construction on the new site, which ...

Here at Hodes, we change organisations from the inside out. Whether we’re answering employer branding or engagement problems or bringing new people on board with recruitment marketing, we help ...